A technology evaluation of the Onyx Frontier drug-eluting stent

References

• Gruentzig A. Results from coronary angioplasty and implications for the future. Am Heart J. 1982;103(4 PART 2):779–783.
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med. 1994;331(8):489–495.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991;324(1):13–17.
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294(10):1215–1223. DOI:10.1001/JAMA.294.10.1215
   PubMed Web of Science ®Google Scholar
• Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27(23):2784–2814.
   PubMed Web of Science ®Google Scholar
• Wessely R. New drug-eluting stent concepts. Nat Rev Cardiol. 2010;7(4):194–203.
   PubMed Web of Science ®Google Scholar
• Torii S, Jinnouchi H, Sakamoto A, et al. Drug-eluting coronary stents: insights from preclinical and pathology studies. Nat Rev Cardiol. 2020;17(1):37–51.
   PubMed Web of Science ®Google Scholar
• Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC: Cardiovasc Interv. 2020;13(12):1391–1402.
   PubMed Web of Science ®Google Scholar
• Regazzoli D, Leone PP, Colombo A, et al. New generation bioresorbable scaffold technologies: an update on novel devices and clinical results. J Thorac Dis. 2017;9(S9):9.
   Google Scholar
• Jinnouchi H, Torii S, Sakamoto A, et al. Fully bioresorbable vascular scaffolds: lessons learned and future directions. Nat Rev Cardiol. 2018;16(5):286–304.
   Web of Science ®Google Scholar
• Nicolas J, Pivato CA, Chiarito M, et al. Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench-to-bedside. Cardiovasc Res. 2022 Jul;119(3):631–646.
   Web of Science ®Google Scholar
• Watson T, Webster MWI, Ormiston JA, et al. Long and short of optimal stent design. Open Heart. 2017;4(2):e000680.
   PubMedGoogle Scholar
• Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (London, England). 2007;370(9591):937–948.
   PubMed Web of Science ®Google Scholar
• Sousa JE, Costa MA, Abizaid A, et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation. 2005;111(18):2326–2329. DOI:10.1161/01.CIR.0000164271.01172.1A
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Vorpahl M, et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol. 2011;57(4):390–398.
   PubMed Web of Science ®Google Scholar
• Hasebe T, Yohena S, Kamijo A, et al. Fluorine doping into diamond-like carbon coatings inhibits protein adsorption and platelet activation. J Biomed Mater Res A. 2007;83(4):1192–1199.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129(2):211–223. DOI:10.1161/CIRCULATIONAHA.113.001790
   PubMed Web of Science ®Google Scholar
• Yazdani SK, Sheehy A, Pacetti S, et al. Stent coating integrity of durable and biodegradable coated drug eluting stents. J Interv Cardiol. 2016;29(5):483–490.
   PubMed Web of Science ®Google Scholar
• Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663–1674.
   PubMed Web of Science ®Google Scholar
• Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol. 2011;57(16):1700–1708.
   PubMed Web of Science ®Google Scholar
• Nakayoshi T, Ueno T, Sasaki KI, et al. Differential angioscopic findings of neointimal coverage among first-, second-, and next generation drug-eluting stents. Int J Cardiol. 2016;223:450–451.
   PubMed Web of Science ®Google Scholar
• Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol. 2012;59(15):1362–1370.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Koolen JJ, Doros G, et al. Ultrathin bioresorbable-polymer sirolimus-eluting stents versus thin durable-polymer everolimus-eluting stents for coronary revascularization: 3-year outcomes from the randomized BIOFLOW V trial. Cardiovasc Interv. 2020;13(11):1343–1353.
   PubMed Web of Science ®Google Scholar
• Reimers B, Leone PP, Regazzoli D. Thin, thinner, or disappearing stents?: the truth may lie in the middle*. Cardiovasc Interv. 2020;13(11):1354–1356.
   PubMed Web of Science ®Google Scholar
• Lee SWL, Tam FCC, Chan KKW, et al. Establishment of healing profile and neointimal transformation in the new polymer-free biolimus A9-coated coronary stent by longitudinal sequential optical coherence tomography assessments: the EGO-BIOFREEDOM study. EuroIntervention. 2018;14(7):780–788.
   PubMed Web of Science ®Google Scholar
• Tada N, Virmani R, Grant G, et al. Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv. 2010;3(2):174–183.
   PubMed Web of Science ®Google Scholar
• Jensen LO, Maeng M, Raungaard B, et al. Randomized comparison of the polymer-free biolimus-coated biofreedom stent with the ultrathin strut biodegradable polymer sirolimus-eluting orsiro stent in an all-comers population treated with percutaneous coronary intervention: the SORT OUT IX trial. Circulation. 2020;141(25):2052–2063. DOI:10.1161/CIRCULATIONAHA.119.040241
   PubMed Web of Science ®Google Scholar
• Romaguera R, Salinas P, Gomez-Lara J, et al. Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. Eur Heart J. 2022;43(13):1320–1330.
   PubMed Web of Science ®Google Scholar
• Pivato CA, Leone PP, Petriello G, et al. The Cre8 amphilimus-eluting stent for the treatment of coronary artery disease: safety and efficacy profileVol. 17. Taylor & Francis; 2020. DOI:10.1080/17434440.2020.1740587
   Google Scholar
• Rozemeijer R, Stein M, Voskuil M, et al. Randomized all-comers evaluation of a permanent polymer zotarolimus-eluting stent versus a polymer-free amphilimus-eluting stent. Circulation. 2019;139(1):67–77. DOI:10.1161/CIRCULATIONAHA.118.037707
   PubMed Web of Science ®Google Scholar
• Bridges J, Cutlip D. Advances in drug eluting stents - focus on the Endeavor(®) zotarolimus stent. Med Devices. 2009;2:1–8.
   Google Scholar
• Sanz-Sánchez J, Leone PP, Goel R, et al. Zotarolimus-eluting stents. Interv Cardiol. 2022 Jun;350–358. DOI:10.1002/9781119697367.CH33
   Google Scholar
• Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65(8):805–815.
   PubMed Web of Science ®Google Scholar
• Udipi K, Melder RJ, Chen M, et al. The next generation endeavor resolute stent: role of the BioLinx polymer system. EuroIntervention. 2007;3(1):137–139. http://www.ncbi.nlm.nih.gov/pubmed/19737697
   PubMedGoogle Scholar
• Banerjee S. The resoluteTM integrity zotarolimus-eluting stent in coronary artery disease: a review. Cardiol Ther. 2013;2(1):17–25.
   PubMedGoogle Scholar
• Piriou PG, Guérin P, Bonin M, et al. Radiopacity of coronary stents, an in vitro comparative study. Cardiovasc Eng Technol. 2020;11(6):719–724.
   PubMed Web of Science ®Google Scholar
• Price MJ, Saito S, Shlofmitz RA, et al. First report of the resolute Onyx 2.0-mm zotarolimus-eluting stent for the treatment of coronary lesions with very small reference vessel diameter. JACC Cardiovasc Interv. 2017;10(14):1381–1388. DOI:10.1016/j.jcin.2017.05.004
   PubMed Web of Science ®Google Scholar
• Ng J, Foin N, Ang HY, et al. Over-expansion capacity and stent design model: an update with contemporary DES platforms. Int J Cardiol. 2016;221:171–179.
   PubMed Web of Science ®Google Scholar
• Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136–146. DOI:10.1056/NEJMoa1004130
   PubMed Web of Science ®Google Scholar
• von Birgelen C, Basalus MWZ, Tandjung K, et al. a randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59(15):1350–1361.
   PubMed Web of Science ®Google Scholar
• Park KW, Kang SH, Kang HJ, et al. a randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: hOST-ASSURE (harmonizing optimal strategy for treatment of cor. J Am Coll Cardiol. 2014;63(25):2805–2816. DOI:10.1016/j.jacc.2014.04.013
   PubMed Web of Science ®Google Scholar
• Von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413–423.
   PubMed Web of Science ®Google Scholar
• Raungaard B, Jensen LO, Tilsted HH, et al. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. Lancet (London, England). 2015;385(9977):1527–1535.
   PubMed Web of Science ®Google Scholar
• Konigstein M, Smits PC, Love MP, et al. Randomized comparison of ridaforolimus-eluting and zotarolimus-eluting coronary stents: 2-year clinical outcomes from the BIONICS and NIREUS trials. JACC: Cardiovasc Interv. 2020;13(1):86–93. DOI:10.1016/j.jcin.2019.08.019
   PubMed Web of Science ®Google Scholar
• Yeh RW, Silber S, Chen L, et al. 5-year safety and efficacy of resolute zotarolimus-eluting stent: the RESOLUTE global clinical trial program. JACC: Cardiovasc Interv. 2017;10(3):247–254. DOI:10.1016/j.jcin.2016.11.004
   PubMed Web of Science ®Google Scholar
• von Birgelen C, Zocca P, Buiten RA, et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomi. Lancet. 2018;392(10154):1235–1245. DOI:10.1016/S0140-6736(18)32001-4
   PubMed Web of Science ®Google Scholar
• Buiten RA, Ploumen EH, Zocca P, et al. Thin composite-wire-strut zotarolimus-eluting stents versus ultrathin-strut sirolimus-eluting stents in BIONYX at 2 years. JACC: Cardiovasc Interv. 2020;13(9):1100–1109.
   PubMed Web of Science ®Google Scholar
• Ploumen EH, Buiten RA, Zocca P, et al. First report of 3-year clinical outcome after treatment with novel resolute Onyx stents in the randomized BIONYX trial. Circ J. 2021;85(11):1983–1990.
   PubMed Web of Science ®Google Scholar
• Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020;382(13):1208–1218.
   PubMed Web of Science ®Google Scholar
• Windecker S, Latib A, Kedhi E, et al. Polymer-based versus polymer-free stents in high bleeding risk patients: final 2-year results from Onyx ONE. JACC: Cardiovasc Interv. 2022;15(11):1153–1163.
   PubMed Web of Science ®Google Scholar
• Tam CC, Chan K, Lam S, et al. One-year clinical outcomes of patients implanted with a resolute Onyx zotarolimus-eluting stent. J Int Med Res. 2018;46(1):457–463. DOI:10.1177/0300060517717826
   PubMed Web of Science ®Google Scholar
• Price MJ, Shlofmitz RA, Spriggs DJ, et al. Safety and efficacy of the next generation resolute Onyx zotarolimus-eluting stent: primary outcome of the RESOLUTE ONYX core trial. Catheter Cardiovasc Interv. 2018;92(2):253–259. DOI:10.1002/ccd.27322
   PubMed Web of Science ®Google Scholar
• Kim Y, Oh SS, Jeong MH, et al. Comparison of short-term clinical outcomes between resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: results from the Korea Acute Myocardial infarction Registry (KAMIR). Cardiol J. 2019;26(5):469–476.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Kirtane AJ, Windecker S, et al. One-month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients. Circ Cardiovasc Interv. 2020;13(11):222–232.
   Web of Science ®Google Scholar
• Jen HL, Wang YC, Tsao TP, et al., Percutaneous coronary intervention for very small vessels with the use of a newer-generation 2.0 mm drug-eluting stent. J Invasive Cardiol. 2021;33(7):E565–574. Accessed Aug 28, 2022 https://pubmed.ncbi.nlm.nih.gov/34224385/.
   PubMed Web of Science ®Google Scholar
• Roleder T, Kedhi E, Berta B, et al. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: onyx one-month optical coherence tomography study. Postep Kardiol Interwencyjnej. 2019;15(2):143–150. DOI:10.5114/aic.2019.86009
   PubMed Web of Science ®Google Scholar
• Jinnouchi H, Sato Y, Cheng Q, et al. Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: implications for short-term dual anti-platelet therapy. Int J Cardiol. 2021;327:52–57.
   PubMed Web of Science ®Google Scholar
• Zocca P, Kok MM, Tandjung K, et al. 5-year outcome following randomized treatment of all-comers with zotarolimus-eluting resolute integrity and everolimus-Eluting PROMUS element coronary stents: final report of the DUTCH PEERS (TWENTE II) Trial. JACC: Cardiovasc Interv. 2018;11(5):462–469. DOI:10.1016/j.jcin.2017.11.031
   PubMed Web of Science ®Google Scholar
• Bundhun PK, Yanamala CM, H WQ. Comparing stent throm- bosis associated with zotarolimus eluting stents versus everolimus eluting stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials. BMC Cardiovasc Disord. 2017;17:1.
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Hear J. 2019;40(31):2632–2653. DOI:10.1093/eurheartj/ehz372
   PubMed Web of Science ®Google Scholar
• Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: jACC guideline comparison. J Am Coll Cardiol. 2018;72(23 Pt A):2915–2931.
   PubMed Web of Science ®Google Scholar
• Piccolo R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019;393(10190):2503–2510.
   PubMed Web of Science ®Google Scholar
• Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–2047.
   PubMed Web of Science ®Google Scholar
• Varenne O, Cook S, Sideris G, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391(10115):41–50. DOI:10.1016/S0140-6736(17)32713-7
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385(18):1643–1655.
   PubMed Web of Science ®Google Scholar
• Zocca P, Kok MM, van der Heijden LC, et al. High bleeding risk patients treat with very thin-strut biodegrad polym or thin-strut durable polym drug-eluting stents BIO-RESORT trial. Cardiovasc Drugs Ther. 2018;32(6):567–576. DOI:10.1007/s10557-018-6823-9
   PubMed Web of Science ®Google Scholar
• Silber S, Kirtane AJ, Belardi JA, et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. Eur Hear J. 2014;35:1949–1956.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Kirtane AJ, Mehran R, et al. Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1-month dual antiplatelet therapy following PCI: analysis from the Onyx ONE clear study. Catheter Cardiovasc Interv. 2022;99(3):583–592.
   PubMed Web of Science ®Google Scholar
• Mehran R, Cao D, Angiolillo DJ, et al. 3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation. JACC: Cardiovasc Interv. 2021;14(17):1870–1883.
   PubMed Web of Science ®Google Scholar
• Kirtane AJ, Stoler R, Feldman R, et al. Primary results of the EVOLVEshort DAPT study: evaluation of 3-month dual antiplatelet therapy in high bleeding risk patients treated with a bioabsorbable polymer-coated everolimus-eluting stent. Circ Cardiovasc Interv. 2021;14(3). DOI:10.1161/CIRCINTERVENTIONS.120.010144
   Web of Science ®Google Scholar
• Ploumen EH, Buiten RA, Zocca P, et al. Acute myocardial infarction treated with novel resolute Onyx and Orsiro stents in the randomized BIONYX trial. Catheter Cardiovasc Interv. 2021;98(2):E188–196.
   PubMed Web of Science ®Google Scholar
• Iglesias JF, Muller O, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019;394(10205):1243–1253.
   PubMed Web of Science ®Google Scholar
• Chichareon P, Modolo R, Kogame N, et al. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis. 2020;295:45–53.
   PubMed Web of Science ®Google Scholar
• Ploumen EH, Buiten RA, Kok MM, et al. Treating diabetic all-comers with contemporary drug-eluting stents: prespecified comparisons from the BIO-RESORT and the BIONYX randomized trials. Int J Cardiol. 2021;325:37–44.
   PubMed Web of Science ®Google Scholar
• Kaul U, Bangalore S, Seth A, et al. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes. N Engl J Med. 2015;373(18):1709–1719.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Mauri L, Koolen JJ, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017;390(10105):1843–1852.
   PubMed Web of Science ®Google Scholar
• Konigstein M, Ben-Yehuda O, Smits PC, et al. Outcomes among diabetic patients undergoing percutaneous coronary intervention with contemporary drug-eluting stents: analysis from the BIONICS randomized trial. JACC: Cardiovasc Interv. 2018;11(24):2467–2476.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Hear J. 2019;40(2):87–165. DOI:10.1093/eurheartj/ehy394
   PubMed Web of Science ®Google Scholar
• Mehilli J, Richardt G, Valgimigli M, et al. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol. 2013;62(22):2075–2082.
   PubMed Web of Science ®Google Scholar
• Lee PH, Kwon O, Ahn JM, et al. Safety and effectiveness of second-generation drug-eluting stents in patients with left main coronary artery disease. J Am Coll Cardiol. 2018;71(8):832–841.
   PubMed Web of Science ®Google Scholar
• Tarantini G, Fovino LN, Varbella F, et al. a large, prospective, multicentre study of left main PCI using a latest-generation zotarolimus-eluting stent: the ROLEX study. EuroIntervention. 2022 Aug. DOI:10.4244/EIJ-D-22-00454
   Google Scholar
• Parikh MA, Soverow J, Leon MB, et al. Outcomes of stenting extra- small (≤2.25 mm) vessels using the resolute zotarolimus-eluting stent (R-ZES). EuroIntervention. 2016;12(10):1215–1221. DOI:10.4244/EIJV12I10A200
   PubMed Web of Science ®Google Scholar
• Cannon LA, Simon DI, Kereiakes D, et al. The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the spirit small vessel trial. Catheter Cardiovasc Interv. 2012;80(4):546–553. DOI:10.1002/ccd.23397
   PubMed Web of Science ®Google Scholar